Coherus Oncology (CHRS) Amortizatization of Intangibles (2015 - 2023)

Coherus Oncology (CHRS) has 9 years of Amortizatization of Intangibles data on file, last reported at -$428000.0 in Q4 2023.

• For the quarter ending Q4 2023, Amortizatization of Intangibles fell 153.5% year-over-year to -$428000.0; the trailing twelve-month figure through Dec 2023 stood at $726000.0 (down 85.87% YoY), and the FY2024 full-year result was $4.2 million, up 72.79% from the prior year.
• Amortizatization of Intangibles eased to -$428000.0 in Q4 2023, from $255000.0 in the prior quarter.
• In the past five years, Amortizatization of Intangibles ranged from a high of $3.7 million in Q1 2022 to a low of -$428000.0 in Q4 2023.
• A 5-year average of $685950.0 and a median of $327000.0 in 2020 frame the typical range for Amortizatization of Intangibles.
• Across the five-year window, Amortizatization of Intangibles jumped 1143.18% in 2019 and slumped 153.5% in 2023, its largest moves.
• Tracing CHRS's Amortizatization of Intangibles over 5 years: stood at $2.2 million in 2019, then slumped by 54.98% to $989000.0 in 2020, then gained by 11.93% to $1.1 million in 2021, then decreased by 27.73% to $800000.0 in 2022, then tumbled by 153.5% to -$428000.0 in 2023.
• Business Quant data shows CHRS's Amortizatization of Intangibles at -$428000.0 in Q4 2023, $255000.0 in Q3 2023, and $243000.0 in Q2 2023.